Ran Yihong, Huang Xiaozhun, Che Xu, Chen Dong
National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Heliyon. 2025 Jan 16;11(2):e42010. doi: 10.1016/j.heliyon.2025.e42010. eCollection 2025 Jan 30.
Primary hepatocellular carcinoma (HCC) is a common malignancy with high morbidity and mortality. Despite progress in systemic therapies, survival in advanced HCC remains poor due to patient heterogeneity and individual differences, necessitating a personalized approach rather than relying solely on guidelines. Here, we present an exceptional case study in which a systematic regimen without immune checkpoint inhibitors was chosen based on the patient's specific genetic test results. Remarkably effective with long-term survival benefits were observed as a result. This case underscores the importance of incorporating tumor profiling and personalized treatment plans, in addition to adhering to guidelines and standards, for delivering more efficacious and well-tolerated therapeutic options to patients with liver cancer.
原发性肝细胞癌（HCC）是一种常见的恶性肿瘤，发病率和死亡率都很高。尽管全身治疗取得了进展，但由于患者的异质性和个体差异，晚期HCC患者的生存率仍然很低，因此需要采用个性化方法，而不是仅仅依赖指南。在此，我们展示了一个特殊的病例研究，其中根据患者的特定基因检测结果选择了一种不使用免疫检查点抑制剂的系统治疗方案。结果观察到该方案非常有效，并带来了长期生存益处。该病例强调了除遵循指南和标准外，纳入肿瘤分析和个性化治疗计划对于为肝癌患者提供更有效且耐受性良好的治疗选择的重要性。
